These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1085 related articles for article (PubMed ID: 19460503)

  • 41. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
    Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial of immunosuppressive regimens in renal transplantation.
    Guerra G; Ciancio G; Gaynor JJ; Zarak A; Brown R; Hanson L; Sageshima J; Roth D; Chen L; Kupin W; Tueros L; Ruiz P; Livingstone AS; Burke GW
    J Am Soc Nephrol; 2011 Sep; 22(9):1758-68. PubMed ID: 21807891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
    Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
    Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A; Iwai T; Uchida J
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclosporine and mycophenolate mofetil 48 hours before renal transplantation enables the use of low cyclosporine doses and achieves better graft function.
    Maamoun H; Soliman A; Zayed B
    Transplant Proc; 2010 Dec; 42(10):4033-6. PubMed ID: 21168619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
    Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
    Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L
    Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Ko WJ; Tsao CI; Sun CD
    Transplant Proc; 2008 Oct; 40(8):2607-8. PubMed ID: 18929814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.